Form 4 Filing by Stephen Mayo of Allogene Therapeutics, Inc.

Stephen Mayo, a director at Allogene Therapeutics, Inc. (ALLO), acquired 144,400 stock options on June 18, 2026. These options, with an exercise price of $2.00, are for the company's Common Stock and vest in 12 equal monthly installments. The acquisition is reported on Form 4, with the transaction code "A" indicating acquisition. Mr. Mayo now holds 144,400 shares following this transaction. The filing was signed by Earl Douglas as Attorney-in-Fact on June 23, 2026. The options expire on June 18, 2036.